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Abstract Endotbelin may play a role in atherosclerosis as it 
causes smooth muscle cell proliferation and its levels are elevated 
in patients with atherosclerosis. We report that interleukin-l/3 is 
a potent inducer of endothelin receptor expression in cultured 
human vascular smooth muscle cells. The effect is dose- and 
time-dependent and is due to an increase in receptor number. 
Endothelin receptor mRNA levels are also elevated. Interleukin- 
lfi is a major regulator of endothelin release so, together with its 
effects on endothelin receptors, it may be responsible for a gener- 
alized activation of the endothelin system in diseased vessels. 
Key words: Endothelin receptor; Interleukin-lp; Smooth 
muscle cell; Atherosclerosis 
1. Introduction 
Endothelin-1 (ET) is a potent vasoconstrictor synthesized 
mainly by endothelial cells [l], which also mediates a number 
of other effects including cell proliferation. ET is a mitogen for 
transformed mouse fibroblasts [2,3] and rat vascular smooth 
muscle cells (VSMC) in monolayer cultures [4]. Its effects on 
VSMC proliferation were particularly potent in organ cultures 
of rat arterial segments [5]. It also enhances restenosis and 
intimal hyperplasia after balloon catheter injury of rat artery 
[6,7], a widely used animal model in which the arterial wall is 
denuded of its endothelium, showing that ET is mitogenic for 
VSMC in vivo. In addition to its mitogenic effects on VSMC, 
ET can also cause vessels to become prone to vasospasm [8], 
depriving tissue of blood supply. Levels of ET are elevated in 
the plasma of patients with atherosclerosis and in the athero- 
sclerotic plaques themselves [9, lo] and some evidence suggests 
that ET receptors are more abundant in plaques than in normal 
vascular wall tissue [l I]. This suggests that ET and its receptors 
may play some role in the pathogenesis of atherosclerosis and 
that the regulation of expression of these molecules is therefore 
important to an understanding of this condition. ET receptor 
expression in cultured rat VSMC is enhanced by CAMP [ 121 and 
reduced by dexamethasone [13], and is modulated by certain 
growth factors in human VSMC [14]. We have tested three 
cytokines, interleukin-l/3 (IL-l/I), transforming growth factor-p 
(TGF-P), and tumour necrosis factor-a (TNF-a) for their pos- 
sible regulatory effects on ET, subtype-receptor (ET,-R) ex- 
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pression. All of these cytokines are present in atherosclerotic 
plaques [15] though they are not normally present in healthy 
artery. Initial results showed that IL-l/? elevated [12’I]ET bind- 
ing to all VSMC lines tested and so our study concentrated on 
this cytokine. 
2. Materials and methods 
2.1. Cell culture 
Four human VSMC lines designated A, B, C and D were isolated 
from human aorta obtained during transplant operations as previously 
described [16], and cultured in Dulbecco’s modified Eagle’s medium, 
DMEM, (Sigma, Poole, UK) supplemented with 10% v/v heat-inac- 
tivated foetal calf serum (FCS) (Seralab, Crawley Down, UK), 100 
units/ml penicillin, 100 &ml streptomycin and 10 mM HEPES (all 
from Sigma). 
2.2. Receptor binding assays 
For [‘ZSI]ET binding experiments, cells were plated into 48-well clus- 
ters (Costar, High Wycombe, UK) at a density of 4x IO4 cells per well, 
incubated in culture medium for three days, then growth-arrested for 
48 h in growth-arrest medium (DMEM/O.S%FCS) prior to the assay. 
Agonists were added 24 h before the assay except for time course 
experiments in which cells were pre-treated with IL-lp for between 
2 and 48 h. Radio-receptor assays were done by washing the cells once 
with binding buffer (Earle’s balanced salts (EBSS) plus 0.2% bovine 
serum albumin (Sigma) and 10 mM HEPES), then incubating for 90 
min in binding buffer plus [“‘I]ET (NEN, USA; 2200 Ci/mmol) at a 
concentration of 80 pM at 37°C in a 5% CO, incubator. Non-specific 
binding was measured by adding excess unlabelled ET (Bachem, Tor- 
rance, CA, USA) to a final concentration of 1pM. After incubation, the 
wells were washed once with binding buffer, then with 1 M NaOH to 
solubilize the bound radioactivity. For Scatchard analysis the concen- 
tration of radiolabel was varied over a range of 9-285 pM. 
2.3. Preparation of RNA 
Total RNA was prepared from 75 cm’ flasks of cultured cells by lysis 
with guanidine isothiocyanate buffer followed by centrifugation over 
a CsCl cushion [17]. RNA was found to be intact by electrophoresis on 
agarose/formaldehyde gels and concentrations were estimated by meas- 
uring absorbance at 260 nm. 
2.4. RTIPCR 
2.4.1. cDNA synthesis. For each reaction, 1 pg of RNA was incu- 
bated at 37°C in 20 ~1 RT buffer (Promega, Southampton, UK) con- 
taining RNAsin, 0.1 pg random hexamer primers and 2 units of MMLV 
reverse transcriptase (all from Promega). After 1 h, the reaction was 
terminated by heating to 94°C for 5 min. The volume was then diluted 
to 100~1 with double-distilled water and 10~1 of this solution was used 
for the PCR. 
2.4.2. Polymerase chuin reuction. Reactions were carried out in 
a thermal cycler (Cetus-Perkin Elmer, USA) in a final volume of 50 ~1 
of Taq buffer (Promega) containing dNTPs at 0.2 mM each, 200 ng of 
each primer and 2.5 units of Taq polymerase (Promega). Each cycle 
consisted of I .5 min denaturation at 94”C, 1 min annealing at 62°C and 
1.5 min primer extension at 72°C. Two sets of primers were used, both 
of which have been used and reported elsewhere, one set specific for 
ET,-R [18] and the other set specific for glyceraldehyde-3-phosphate 
dehydrogenase (G-3-PDH) as a control for the cDNA synthesis reac- 
tions [19]. The sequences are: ET, forward: CCTTTTGATCACAAT- 
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GACTTT (bp 439459); ET, reverse: TTTGAT GTGGCATTGAG- 
CATACAG (bp 737-714); G-3-PDH forward: TGAAGGTCGGAG- 
TCA ACGGATTTGGT (bp 71-96); G-3-PDH reverse: CATGTGG- 
GCCATGAGGTCCACCAC (bp 1053-1030). Reactions primed with 
ET,-R specific oligos were incubated for 33 cycles and those primed 
with G-3-PDH oligos were given 28 cycles. After PCR, 10~1 aliquots 
of each reaction mixture were electrophoresed on a 2% agarose gel and 
stained with ethidium bromide. 
2.5. Cell proliferation assays 
Cell proliferation in response to agonists was estimated by cell count- 
ing and by [‘Hlthymidine incorporation. For cell counting assays, cells 
were plated in 24-well clusters (Falcon, Oxford, UK) at 4x lo4 per well, 
cultured in DMEM/lO% FCS for 48 h then growth arrested for 48 h 
before the addition of ET. IL-lp or forskolin were added for the final 
24 h of the growth arrest period. The cells were then washed with 
growth-arrest medium and incubated with 1 nM ET in the same me- 
dium for 3 days or, for control cells, in growth arrest medium only. The 
cells were then harvested from each well using trypsin/EDTA and 
counted using a haemocytometer. 
2.6 [‘H]Thymidine incorporation assays 
Cells were plated into 96-well clusters (Falcon) at 1~10~ cells per 
well, cultured for 3 days in DMEM/lO% FCS then growth-arrested for 
48 h. IL-l/? was added for the last 24 h of the growth arrest period. The 
cells were then stimulated for 24 h with agonists in serum-free medium 
followed by a further 24 h with the addition of 1 ,@Zi/well [3H]thymidine 
(5 Ci/mmol) (Amersham, Bucks, UK). The cells were then trypsin/ 
EDTA-treated and the DNA harvested using a cell harvester (Brandel, 
MD, USA) as described previously [16]. 
3. Results 
3.1. ET-I binding experiments 
Up to four different human VSMC lines designated A, B, C 
and D were used to investigate the effects of pre-treatment with 
three cytokines: IL-lb, TGF-j? and TNF-& on levels of [lz51]ET 
binding to cultured cells. As a positive control 20pM forskolin, 
which is known to increase levels of ET receptor mRNA [12] 
increased [‘251]ET binding in all of the cell lines tested between 
1.3- and 2.1-fold (data not shown). In all of these lines IL-la 
was found to increase the amount of [‘251]ET which bound to 
the cells by 2.3- to 5.3-fold (Table I), or around double the 
range of values found for forskolin. Neither TGF-j? nor TNF-or 
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Fig. 1. Effect of IL- l/7, TNF-a and TGF-/? on specific [“‘I]ET binding 
to cell lines A and B. Confluent monolayers of cells were transferred 
to growth-arrest medium 48 h before the assay. Cytokines were added 
24 h prior to the assay. Each bar represents the specific binding as 
mean t S.E.M. of 3 wells. 
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Fig. 2. Specific [“‘IlET binding to cell lines A and C after various 
lengths of IL-la treatment. Cells were cultured in 48-well plates and 
growth arrested as described. 10 &ml of IL-lb was added between 0 
and 24 h prior to the receptor binding assay. Each point represents the 
specific binding as mean f S.E.M. of 3 wells. 
cell lines tested although TNF-a increased binding quite 
strongly in one of them (Fig. 1). Thus, IL-lb was considered 
the most significant regarding ET receptor expression. [‘*jI]ET 
binding was found to increase within 4 h of addition of IL-Ip 
and reached a maximum after 24 h (Fig. 2).In a separate experi- 
ment, when IL-lp was removed after 24 h of treatment and 
replaced with ordinary medium, [‘*‘I]ET binding was found to 
remain elevated for at least 48 h, remaining at 3S(f l.l)-fold 
above control levels at 48 h after an initial 5.5(f 0.3)-fold in- 
crease. The effect of IL-lp pre-treatment upon [‘*jI]ET binding 
was dose-dependent and was detected at IL-l/? concentrations 
as low as 10 pg/ml (Fig. 3). Scatchard analysis showed that the 
effect was due to an increase in the number of binding sites per 
cell with no significant change in Kd (Fig. 4). For cells pre- 
treated 24 h with 10 ng/ml IL-lp (open squares), B,,, = 4.5 
fmol/104 cells and Kd = 55 pM; for untreated cells (full squares) 
B max = 0.9 fmol/104 cells and Kd = 31 pM. 
3.2. Cell proliferation studies 
In monolayer cultures ET has been shown to be mitogenic 
for VSMC from some sources but not all. We investigated the 
possibility that pre-treatment with IL-ID or with forskolin, 
which raises intracellular CAMP levels, followed by ET treat- 
ment would lead to cell proliferation. 24 h of pre-treatment with 
10 ng/ml IL-la or 20 PM forskolin followed by incubation with 
1pM ET for 3 days did not lead to an increase in cell number. 
In each case cell numbers remained at between 90% and 105% 
of the control values. When cells were pre-treated with IL-l,8 
for 24 h followed by 24 h treatment with 1 PM ET in the 
presence of [3H]thymidine no increase in thymidine incorpora- 
tion above that obtained with IL-l/3 alone was observed (data 
not shown). 
3.3. Estimation of ET,-R mRNA 
In preliminary binding studies with ET isopeptides we estab- 
lished that ET,-R is the predominant receptor subtype in these 
cells (data not shown). In order to assess whether elevated ET 
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Fig. 3. Dose-dependent effect of IL-ID on elevation of [“‘IlET binding 
to cell lines A and B. Growth-arrested HVSMC were treated for 24 h 
with a range of concentrations of IL-l/I from 10 pg/ml to 10 ng/ml 
before the receptor binding assay. Each bar represents the specific 
binding as mean f S.E.M. of 3 wells, 
binding in response to IL-l/? exposure was accompannied by 
an increased abundance of ET receptor mRNA, we prepared 
RNA from IL-l/? treated and non-treated cultured human 
VSMC and performed RT/PCR using primers specific for the 
ET,-R subtype of ET receptors. Our results show that there is 
more ET,-R mRNA in cells treated with IL-l/I than in non- 
treated cells (Fig. 5A). The amount of mRNA was elevated by 
4 h treatment and remained elevated after 24 h. Forskolin, 
previously shown to increase ET,-R mRNA in rat VSMC [12] 
was also found to elevate ET,-R mRNA above control levels 
in our human VSMC. Increasing amounts of cDNA in the PCR 
reaction gave a proportionally higher amount of product indi- 
cating that under these conditions, the amplification was semi- 
quantitative. No product was seen in the absence of cDNA 
(data not shown). The same cDNA samples were also used in 
reactions primed with oligonucleotides specific for glyceralde- 
hyde-3-phosphate dehydrogenase, an enzyme whose mRNA 
is thought to remain constant in the cell under most 
circumstances, as an indication that the amount of RNA 
used in each reverse transcription reaction was the same 
(Fig. 5B). 
4. Discussion 
It is reasonable to hypothesize that increased expression of 
endothelin receptors may be involved in the pathogenesis of 
cardiovascular diseases such as atherosclerosis. Some prelimi- 
nary in vitro data suggests that ET receptors are elevated in 
atherosclerotic plaques [ll]. We have sought to identify the 
factors which may be responsible for signalling such an eleva- 
tion in ET receptor expression. A similar approach has been 
taken before but using rat VSMC [12,13,21]. Human VSMC 
have been used in only one study [14] but no details of the 
number of lines used was provided. In our experiences, human 
VSMC lines demonstrate large variations with respect to 
expression of receptors and response to mediators. Hence in 
this study we used various potential regulators of the endothe- 
lin system on at least four independantly established human 
VSMC lines. 
Table 1 
Specific binding of [“‘IlET to four human VSMC lines. Cells were 
cultured in 4%well plates as described in section 2 and treated with 10 
ng/ml of IL-la for 24 h prior to assay. Each figure shows the specific 
binding as the mean of three individual wells with S.E.M. in brackets. 
Specific [lz51]ET bound (c.p.m./104 cells) 
Cell line Control IL-l,!? treated Ratio of 
treated/control 
A 162 (68) 612 (63) 3.8 
B 2846 (102) 6841 (428) 2.4 
C 681 (62) 3610 (73) 5.3 
D 1083 (44) 2536 (67) 2.3 
In all our cell lines forskolin up-regulated [“‘IlET binding 
consistent with previous observations [12]. However, the re- 
sponse to cytokines was more variable. TGF;B either had no 
effect or slightly down-regulated binding in some cells, whereas 
TNF-cl strongly up-regulated binding in one cell line only, with 
smaller effects on others. IL-la was the only cytokine to consis- 
tently up-regulate [‘251]ET binding in this system in all cell lines 
tested and hence this observation was examined in more detail. 
The effect of IL-l/I was dose and time dependent but could not 
be reversed after the removal of the IL-lp stimulus. This may 
be due to IL-l/I remaining bound to the receptors after the cells 
were washed. The time course of the increase in binding and 
the fact that the ET,-R mRNA levels are elevated for up to 24 
h after the initial stimulus suggests the effect is due to increased 
receptor synthesis and subsequently increased receptor expres- 
sion on the cell surface. 
One of the consequences of increased receptor expression 
might be an increased mitogenic response to exogenous ET but 
this was not observed, either as an increase in cell number or 
in [3H]thymidine incorporation. As we [20] and others have 
observed that the mitogenic effect of ET in monolayer cultures 
is weak or non-existent, this effect was not too surprising. 
However, this experiment could be tested in the organotypic 
cultures of vessels where the mitogenic potency of ET is very 
high. 
0 1 2 3 4 5 
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Fig 4. Scatchard plot of ET binding to HVSMC line C. Open 
squares = cells pre-treated 24 h with 10 @ml IL-lp; full 
squares = untreated cells. 
164 P Newman et al. I FEBS Leftrrs 363 (I 995) 161-164 
G3PDH 
~983 bp 
Fig. 5. Analysis of ET,-R mRNA in control and IL-l/I treated human 
VSMC. RT/PCR was performed as described in section 2. PCR prod- 
ucts derived from RNA prepared from control HVSMC (lane 1); 4 h 
10 ng/ml IL-l/I-treated cells (lane 2); 24 h IL-l/I-treated cells (lane 3); 
24 h, 20 PM forskolin-treated cells (lane 4). PCR-products are shown 
from reactions using: (a) ET,-R specific primers giving a product of 
oredicted size of 299 bo: (b) G-3-PDH specific mimers giving a product I__, _ . _ _ 
of predicted size 923 bp. Only one band was obtained in each reaction 
so only the relevant part of each gel is shown. Similar results were 
obtained with two cell lines. 
IL-la is a pro-inflammatory cytokine which is elevated in the 
vessel wall in atherosclerosis [22]. It is a potent inducer of ET 
in human umbilical vein endothelial cells (HUVEC) [23] of the 
vessel wall and the current study shows that it also elevates ET 
receptors on the smooth muscle making it the only cytokine 
known to have this dual effect. In the ‘response to injury’ 
hypothesis of atherosclerosis [15], injury to the endothelium is 
the initiating event. The increased expression of IL-lp in this 
situation may well, via elevation of ET and its receptor, induce 
VSMC proliferation and also make the vessel wall more prone 
to vasospastic events. 
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